{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T07:54:33Z","timestamp":1767772473177},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>The study aims to define the effect of different dose strategies on ophthalmic complications in patients with Graves\u2019 disease (GD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>All the patients with GD and no or inactive ophthalmopathy (clinical activity score; CAS &lt; 3) underwent Snellen chart examination, measurement of proptosis, thyroid volume, and radioactive iodine uptake, and randomized into 1 of 3 groups. In group 1, all the patients received fixed low dose (FLD) of 259 MBq of <jats:sup>131<\/jats:sup>I, whereas in group 2, all the patients received fixed high dose (FHD) of 555 MBq, and in group 3, calculated dose (CD) was administered to deliver 5.55 MBq\/g (thyroid weight) of <jats:sup>131<\/jats:sup>I. All examinations were repeated 6 months after treatment. The measurement of thyroid function tests and clinical examination were repeated after 12 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We studied 92 patients (58 female and 34 male) with mean age of 38.2 \u00b1 12.0 years. Overall, 29, 32, and 31 patients were studied in FLD, FHD, and CD groups, respectively. The patients in CD received a mean activity of 240.5 MBq. The 3 groups were not significantly different regarding age, sex ratio, radioactive iodine uptake, smoking, visual acuity, and proptosis. The response rate 12 months after radioactive iodine therapy was 66.7%, 94.4%, and 92.9% in FLD, FHD, and CD groups, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.05). Overall, CAS was increased significantly after treatment. Delta proptosis and delta CAS were increased significantly in FHD group compared with other groups (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05). The highest increment in proptosis was seen in FHD group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The administration of 5.55 MBq\/g of <jats:sup>131<\/jats:sup>I has fewer ophthalmic complications compared with high fixed dose model and is more effective than low fixed dose strategy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000003086","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T21:30:29Z","timestamp":1590010229000},"page":"514-518","source":"Crossref","is-referenced-by-count":10,"title":["Effect of Different 131I Dose Strategies for Treatment of Hyperthyroidism on Graves\u2019 Ophthalmopathy"],"prefix":"10.1097","volume":"45","author":[{"given":"Shahrara","family":"Ariamanesh","sequence":"first","affiliation":[{"name":"Nuclear Medicine Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narjess","family":"Ayati","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Mazloum Khorasani","sequence":"additional","affiliation":[{"name":"Metabolic Syndrome Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zohreh","family":"Mousavi","sequence":"additional","affiliation":[{"name":"Metabolic Syndrome Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Kiavash","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Mashhad University of Medical Sciences, Mashhad, Iran."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Kiamanesh","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Rasoul","family":"Zakavi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","year":"2016","journal-title":"Thyroid"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1089\/thy.2005.15.1279","article-title":"Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery","volume":"15","year":"2005","journal-title":"Thyroid"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3803\/EnM.2016.31.1.168","article-title":"Comparison of fixed versus calculated activity of radioiodine for the treatment of Graves\u2019 disease in adults","volume":"31","year":"2016","journal-title":"Endocrinol Metab (Seoul)"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12020-017-1253-1","article-title":"Calculating the incalculable. Optimal radioiodine dose in Graves' hyperthyroidism","volume":"56","year":"2017","journal-title":"Endocrine"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","article-title":"Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of GO","volume":"158","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/nrendo.2013.193","article-title":"Diagnosis and management of Graves disease: a global overview","volume":"9","year":"2013","journal-title":"Nat Rev Endocrinol"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000490384","article-title":"2018 European Thyroid Association Guideline for the Management of Graves' hyperthyroidism","volume":"7","year":"2018","journal-title":"Eur Thyroid J"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s40618-016-0505-x","article-title":"Management of hyperthyroidism due to Graves' disease: frequently asked questions and answers (if any)","volume":"39","year":"2016","journal-title":"J Endocrinol Invest"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves' ophthalmopathy","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"bib10-20230925","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2265.1995.tb02671.x","article-title":"Long-term effects of radioiodine on thyrotrophin receptor antibodies in Graves' disease","volume":"42","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"bib11-20230925","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2265.1982.tb03170.x","article-title":"Effect of radioiodine on stimulatory activity of Graves' immunoglobulins","volume":"16","year":"1982","journal-title":"Clin Endocrinol (Oxf)"},{"key":"bib12-20230925","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1097\/MNM.0000000000000384","article-title":"Methimazole discontinuation before radioiodine therapy in patients with Graves' disease","volume":"36","year":"2015","journal-title":"Nucl Med Commun"},{"key":"bib13-20230925","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1089\/thy.2012.0205","article-title":"Clinical Practice Guidelines for Hypothyroidism in Adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association","volume":"22","year":"2012","journal-title":"Thyroid"},{"key":"bib14-20230925","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.2967\/jnumed.112.105148","article-title":"The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0","volume":"53","year":"2012","journal-title":"J Nucl Med"},{"key":"bib15-20230925","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1365-2265.2007.03097.x","article-title":"Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists","volume":"68","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"bib16-20230925","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1530\/EJE-09-0286","article-title":"Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis","volume":"161","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"bib17-20230925","first-page":"3611","article-title":"Radioiodine treatment of hyperthyroidism-prognostic factors for outcome","volume":"86","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"bib18-20230925","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1210\/jc.2002-020805","article-title":"A randomized comparison of radioiodine doses in Graves' hyperthyroidism","volume":"88","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"bib19-20230925","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40842-018-0071-6","article-title":"Efficacy of radioactive iodine treatment of Graves' hyperthyroidism using a single calculated 131I dose","volume":"4","year":"2018","journal-title":"Clin Diabetes Endocrinol"},{"key":"bib20-20230925","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4103\/2230-8210.139222","article-title":"Comparison of clinical outcome after a fixed dose versus dosimetry-based radioiodine treatment of Graves' disease: results of a randomized controlled trial in Indian population","volume":"18","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"key":"bib21-20230925","first-page":"85","article-title":"Outcome of 131I therapy in hyperthyroidism using a 550MBq fixed dose regimen","volume":"82","year":"2013","journal-title":"Ulster Med J"},{"key":"bib22-20230925","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40658-018-0231-x","article-title":"Impact of different approaches to calculation of treatment activities on achieved doses in radioiodine therapy of benign thyroid diseases","volume":"5","year":"2018","journal-title":"EJNMMI phys"},{"key":"bib23-20230925","first-page":"012503","article-title":"Graves' disease radioiodine-therapy: choosing target absorbed doses for therapy planning","volume":"41","year":"2014","journal-title":"Med Phys"},{"key":"bib24-20230925","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/MNM.0000000000000826","article-title":"Dosimetry-based treatment for Graves' disease","volume":"39","year":"2018","journal-title":"Nucl Med Commun"},{"key":"bib25-20230925","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s00259-007-0419-0","article-title":"Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science?","volume":"34","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib26-20230925","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2967\/jnumed.107.049437","article-title":"Radioiodine therapy and Graves' ophthalmopathy","volume":"49","year":"2008","journal-title":"J Nucl Med"},{"key":"bib27-20230925","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40618-017-0754-3","article-title":"Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients","volume":"41","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"bib28-20230925","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40618-015-0255-1","article-title":"Total thyroid ablation in Graves' orbitopathy","volume":"38","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"bib29-20230925","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1210\/jcem.80.2.7677823","article-title":"Therapeutic controversies. Retro-orbital radiation and radioactive iodide ablation of the thyroid may be good for Graves' ophthalmopathy","volume":"80","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"bib30-20230925","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1365-2265.2008.03279.x","article-title":"Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review","volume":"69","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"bib31-20230925","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1210\/jc.2009-0747","article-title":"Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131","volume":"94","year":"2009","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:09:28Z","timestamp":1695622168000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003086","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,20]]}}}